Using elliptical iron glycolate nanosheets as precursors, elliptical Fe3O4/C core-shell nanorings (NRs) [25 ± 10 nm in wall thickness, 150 ± 40 nm in length, and 1.6 ± 0.3 in long/short axis ratio] are synthesized via a one-pot hydrothermal route. The surface-poly(vinylpyrrolidone) (PVP)-protected-glucose reduction/carbonization/Ostwald ripening mechanism is responsible for Fe3O4/C NR formation. Increasing the glucose/precursor molar ratio can enhance carbon contents, causing a linear decrease in saturation magnetization (Ms) and coercivity (Hc). The Fe3O4/C NRs reveal enhanced low-frequency microwave absorption because of improvements to their permittivity and impedance matching. A maximum RL value of -55.68 dB at 3.44 GHz is achieved by Fe3O4/C NRs with 11.95 wt % C content at a volume fraction of 17 vol %. Reflection loss (RL) values (≤-20 dB) are observed at 2.11-10.99 and 16.5-17.26 GHz. Our research provides insights into the microwave absorption mechanism of elliptical Fe3O4/C core-shell NRs. Findings indicate that ring-like and core-shell nanostructures are promising structures for devising new and effective microwave absorbers.

TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most common TP53 mutation (R175H, in which arginine at position 175 is replaced with histidine) in complex with a common human leukocyte antigen–A (HLA-A) allele on the cell surface. We describe the structural basis of this specificity and its conversion into an immunotherapeutic agent: a bispecific single-chain diabody. Despite the extremely low p53 peptide-HLA complex density on the cancer cell surface, the bispecific antibody effectively activated T cells to lyse cancer cells that presented the neoantigen in vitro and in mice. This approach could in theory be used to target cancers containing mutations that are difficult to target in conventional ways.

HMGN1 is a novel alarmin that signals through TLR4 and is required for LPS-induced immune responses in vivo.

Akt is a critical protein kinase that drives cancer proliferation, modulates metabolism, and is activated by C-terminal phosphorylation. The current structural model for Akt activation by C-terminal phosphorylation has centered on intramolecular interactions between the C-terminal tail and the N lobe of the kinase domain. Here, we employ expressed protein ligation to produce site-specifically phosphorylated forms of purified Akt1 that are well suited for mechanistic analysis. Using biochemical, crystallographic, and cellular approaches, we determine that pSer473-Akt activation is driven by an intramolecular interaction between the C-tail and the pleckstrin homology (PH)-kinase domain linker that relieves PH domain-mediated Akt1 autoinhibition. Moreover, dual phosphorylation at Ser477/Thr479 activates Akt1 through a different allosteric mechanism via an apparent activation loop interaction that reduces autoinhibition by the PH domain and weakens PIP3 affinity. These results provide a new framework for understanding how Akt is controlled in cell signaling and suggest distinct functions for differentially modified Akt forms.